Ontramab 440 mg Injection contains Trastuzumab, which is used for treating patients with HER2-positive breast cancer and HER2-positive metastatic gastroesophageal adenocarcinoma. This medicine works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of programmed cell death.

FAQs

How does Ontramab 440 mg Injection work?

Ontramab 440 mg Injection contains Trastuzumab, which works by inhibiting the excess production of a protein called human epidermal growth factor receptor 2 (HER2) in mammalian cells. This causes inhibition of the cancer cell growth.

What are the points to be informed to the doctor before starting treatment?

Inform your doctor whether you have received any other cancer treatment. Ontramab 440 mg Injection may cause a decrease in left ventricular ejection fraction, cardiomyopathy, hypersensitivity reactions, pulmonary toxicity, and embryo-fetal toxicity during the treatment. Hence, inform your oncologist if you have any cardiovascular conditions, liver/kidney disease, lung problems, are pregnant, are planning to become pregnant, or are breastfeeding before receiving Ontramab 440 mg Injection.